Cardiovascular Polypill: Rationale, Evidence and Progress to Date


Dr Mark Huffman, Chicago    06 January 2018

Polypill trials have been generally designed to demonstrate bioequivalence rather than differences in clinical outcomes; high quality “usual care” seen in trials limits power. Polypills are essential medicines for secondary ASCVD prevention, especially among low adherers, and the growth of polypill suggests an opening of the marketplace for these combinations.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.